Compare ImmunityBio Inc. Common Stock (IBRX) vs BlackRock TCP Capital Corp (TCPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs BlackRock TCP Capital Corp — how do they compare? ImmunityBio Inc. Common Stock trades at $10.57 (market cap $10.51B), while BlackRock TCP Capital Corp trades at $4.03 (market cap $337.71M). The key difference: ImmunityBio Inc. Common Stock is far larger — about 31.1× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 18.88% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 1 Days and BlackRock TCP Capital Corp for 88 Days on average.
| IBRX | TCPC | |
|---|---|---|
Market Cap | $10.51B | $337.71M |
Volume | 10,445,785 | 436,109 |
Sector | Health | Financials |
52-Week High | $11.55 | $6.20 |
52-Week Low | $1.98 | $3.13 |
Typical Hold Time | 1 Days | 88 Days |
Enterprise Value | $10.97B | $1.09B |
Dividend Yield | — | 18.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TCPC trades at $4.01, up 1.78% with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.22, beating expectations, and announced a $523 million portfolio sale to reduce leverage. Despite negative revenue and net income trends, the stock trades at a discount to book value with a P/B of 0.61. Analyst consensus shows 30.77% buy ratings with no sell recommendations.
The outlook remains cautious due to declining revenue and negative profitability metrics, though strategic portfolio sales and dividend payments provide some stability. Key risks include ongoing net losses and class action litigation, while institutional sentiment appears mixed with technical indicators suggesting near-term bullish momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About BlackRock TCP Capital Corp
BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →
